A mixed blessing for liver transplantation patients—Rapamycin  

作　　者：Guang-Han Fan Chen-Zhi Zhang Feng-Qiang Gao Xu-Yong Wei Sun-Bin Ling Kai Wang Jian-Guo Wang Shu-Sen Zheng Mehrdad Nikfarjam Xiao Xu 

机构地区：[1]Department of Hepatobiliary and Pancreatic Surgery,Affiliated Hangzhou First People’s Hospital,Zhejiang University School of Medicine,Hangzhou 310006,China [2]Zhejiang University School of Medicine,Hangzhou 310058,China [3]Key Laboratory of Integrated Oncology and Intelligent Medicine of Zhejiang Province,Hangzhou 310006,China [4]Institute of Organ Transplantation,Zhejiang University,Hangzhou 310003,China [5]State Key Laboratory of Oncology in South China,Collaborative Innovation Center for Cancer Medicine,Sun Yat-sen University Cancer,Guangzhou 510060,China [6]Westlake Laboratory of Life Sciences and Biomedicine,Hangzhou 310024,China [7]Department of Hepatobiliary and Pancreatic Surgery,The First Affiliated Hospital,Zhejiang University School of Medicine,Hangzhou 310003,China [8]Department of Hepatobiliary and Pancreatic Surgery,Shulan(Hangzhou)Hospital,Hangzhou 310000,China [9]NHC Key Laboratory of Combined Multi-Organ Transplantation,Hangzhou 310003,China [10]Department of Surgery,University of Melbourne,Austin Health,Heidelberg,VIC 3084,Australia

出　　处：《Hepatobiliary & Pancreatic Diseases International》2023年第1期14-21,共8页国际肝胆胰疾病杂志（英文版）

基　　金：supported by grants from the Key Program,National Natural Science Foundation of China(81930016);the National Key Research and Development Program of China(2021YFA1100500);the Major Research Plan of the National Natu-ral Science Foundation of China(92159202);Key Research&Devel-opment Plan of Zhejiang Province(2019C03050);The Construction Fund of Key Medical Disciplines of Hangzhou(OO20200093)。

摘　　要：Background:Liver transplantation(LT)is an effective treatment option for end-stage liver disease.Mammalian target of rapamycin(m TOR)inhibitors,such as rapamycin,are widely used post LT.Data sources:In this review,we focused on the anti-cancer activities and metabolic side effects of rapamycin after LT.The literature available on Pub Med for the period of January 1999-September 2022 was reviewed.The key words were rapamycin,sirolimus,liver transplantation,hepatocellular carcinoma,diabetes,and lipid metabolism disorder.Results:Rapamycin has shown excellent effects and is safer than other immunosuppressive regimens.It has exhibited excellent anti-cancer activity and has the potential in preventing hepatocellular carcinoma(HCC)recurrence post LT.Rapamycin is closely related to two long-term complications after LT,diabetes and lipid metabolism disorders.Conclusions:Rapamycin prevents HCC recurrence post LT in some patients,but it also induces metabolic disorders.Reasonable use of rapamycin benefits the liver recipients.

关 键 词：Liver transplantation RAPAMYCIN Metabolic disease Hepatocellular carcinoma Tumor recurrence 

分 类 号：R657.3[医药卫生—外科学]